Late last week Unigene announced that it had selected a lead peptide compound, designated UGP281, from its obesity program for development. Almost a year ago reported at the Keystone Symposium Conference a short-term study was reported on “Obesity: Novel Aspects of the Regulation of Body Weight” showed a development of a compound, which was orally-administered UGL269, proved to produce a reduction of food intake in dogs by up to 50% and correspondingly reduced body weight. Proceeding studies by Unigene have helped lead to the development of UGP281, a peptide modeled after naturally-occurring hormones which is significantly more potent than UGL269 and achieves the same reduction in food consumption at a lower dose.
“Obesity is one of the fastest-growing public health issues in the United States, as well as in several other countries,” said Dr. Warren Levy, President and CEO of Unigene. “The treatment of obesity is still largely an unmet medical need, and we believe that Unigene’s obesity program offers the potential to identify peptides that may significantly alter food intake in obese individuals and thus reduce the health care cost and the burdens associated with it.”
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline, worldwide rights for its calcitonin manufacturing technology to Novartis and worldwide rights (except for China) for its oral calcitonin program to Tarsa Therapeutics, Inc. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin and PTH analogs. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
